This article is more than 5 years old. Information may no longer be current.
Exciting times for neuromodulators on the horizon
Click Here to Manage Email Alerts
WAIKOLOA, Hawaii — This year and the next will be very exciting for new toxins and fillers on the market, according to Charles M. Boyd, MD, MBA, FACS, at Hawaiian Eye 2019.
Restylane Kysse (Galderma) just completed FDA trials and is specifically designed for use in the lips.
The hyaluronic acid filler has a consistency between Refyne and Defyne, he said.
Teosyal (Teoxane) was FDA approved in late 2017 and is expected to be available in the US in 2019.
“The hyaluronic acid filler is designed to stretch with the skin after injection,” Boyd said. “It is indicated for dynamic lines and etched lines or fine lines around the mouth.”
Polycaprolactone is a biostimulatory filler which is currently in phase 3 trials.
The filler produces new collagen that is more stable and lasts 1.5 to 4 years, which is longer than other biostimulatory fillers, he said.
“I think this is probably the most exciting time that we’ve seen for neuromodulators that I can remember,” Boyd said. “There’s a lot of new competitors as well as new indications, cosmetic as well as therapeutic.”
Phase 3 clinical trial results are completed and will be submitted to the FDA for daxibotulinumtoxin A, also known as RT002, and it could be available in 2020 or 2021.
The trials demonstrated results lasting up to 27 weeks, which is 20% longer than current botulinum toxin A, Boyd said.
Prabotulinumtoxin A has completed a head-to-head comparison with botulinum toxin A and is probably the most similar product to botulinum toxin A that is available, he said.
It expected in the U.S. in February and was approved in South Korea in 2013, he said.
Another product, Bonti, also known as EB-001A, is a serotype E, where most fillers for cosmetic use are serotype A, he said.
This product has a rapid onset of less than 24 hours and a shorter duration of only 2 to 4 weeks.
“This is targeted for first time consumers, or if you have an event where you want a little relaxation and then you want it to go away,” Boyd said.
Lastly, an injectable for the treatment of cellulite, Xiaflex (collagenase clostridium histolyticum) completed its phase 3 with 76% of patients demonstrating highly significant improvement.
With new hyaluronic acid and non-hyaluronic acid fillers, a new injectable treatment for cellulite and at least 3 neurotoxins for cosmetic and therapeutic consumers, there are exciting times ahead, Boyd said. – by Abigail Sutton
Reference: Boyd CM. What’s new on the horizon: Upcoming toxins and fillers. Presented at: Hawaiian Eye; Jan. 19-25, 2019; Waikoloa, Hawaii.
Disclosures: Boyd reports he is on the speakers bureau for Allergan and Galderma and has contracted research for Galderma and Revance.
Editor's note: The 9th paragraph was updated to correct "RT002" and its submission to the FDA.